未知原发性癌症的分子导向疗法:系统性审查和元分析
Chris Labaki1, Marc Eid2, Ziad Bakouny3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
概括
分子定向疗法 (MDT) 显著提高了未知原发性癌症 (CUP) 的存活率. 这一元分析表明,MDT可能成为CUP患者的新标准护理,提供更好的整体存活率和无进展存活率.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 基因组学就是基因组学.
背景情况:
- 未知原发性癌症 (CUP) 的死亡率很高,治疗选择有限.
- 基于的化疗是CUP目前的治疗标准.
- 在临床研究中,分子导向的方法,包括特定于特定地点的和组织不可知的策略,已经显示出不同的结果.
研究的目的:
- 评估分子定向疗法 (MDT) 与CUP患者的实证治疗相比的疗效.
- 评估MDT对CUP的总生存期 (OS) 和无进展生存期 (PFS) 的影响.
- 提供证据支持MDT作为CUP潜在的新护理标准.
主要方法:
- 在主要数据库 (PubMed/MEDLINE,Scopus,Web of Science,Embase,Cochrane Library) 和会议摘要 (ASCO,ESMO) 中进行了全面的文献搜索,截至2024年10月.
- 对六项临床研究进行了元分析,其中包括4项随机对照试验,涉及1644名患者,使用随机效应模型进行了元分析.
- 根据研究设计 (随机与非随机) 进行了子组分析,以评估OS和PFS.
主要成果:
- 与经验治疗相比,MDT显著改善了CUP患者的整体存活率 (OS) (HR:0.75,95%CI:0.62-0.91).
- 在随机 (HR:0.86,95% CI:0.73-1.01) 和非随机 (HR:0.50,95% CI:0.26-0.96) 分组中都观察到一致的OS益处.
- 无进展生存期 (PFS) 也在MDT与实证治疗相比显著提高 (HR:0.79,95%CI:0.67-0.94).
结论:
- 这些发现表明,分子定向疗法 (MDT) 与诊断为CUP的患者的生存结果有所改善.
- 在CUP管理中,MDT在增强OS和PFS方面发挥了重要作用.
- 这些证据支持将MDT视为治疗未知的原发性癌症的潜在新疗法标准.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer
47.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
47.3K
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


